Conditions: Solid Tumor; Small Cell Lung Cancer (SCLC); High Grade Neuroendocrine Cancer; Small Cell Carcinomas of Non-lung Origin; Non-small Cell Lung Cancer (NSCLC); Prostate Cancer; Ovarian Cancer; Renal Carcinoma (Clear and Non-clear Cell); Head and Neck Squamous Cell Carcinoma (HNSCC); Hepatic Cancer; Gastric Cancer; Triple-negative Breast Cancer (TNBC)
Interventions: Drug: EXS74539
Sponsors: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
